Gyre Therapeutics, Inc. (GYRE): Cost of Revenue

Annual figures by period end, from SEC filings.

$5.42M

Year ended 2025-12-31

$6.81M

Trailing 12 months to 2026-06-30

+4.2%

3-year compound annual growth

2022-12-31 Cost of Revenue (USD) 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$5.42M	+39.4%	2026-03-13, From 2025-01-01
2024-12-31	$3.88M	-16.2%	2026-03-13, From 2024-01-01
2023-12-31	$4.64M	-3.3%	2025-03-17, From 2023-01-01
2022-12-31	$4.79M	n/a	2024-03-27, From 2022-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
Gyre Therapeutics, Inc. (GYRE)	2025-12-31	$5.42M	+39.4%
UroGen Pharma Ltd. (URGN)	2025-12-31	$12.45M	+40.2%
Lifecore Biomedical, Inc. (LFCR)	2025-05-25	$88.57M	+2.5%
Siga Technologies Inc (SIGA)	2025-12-31	$29.70M	-5.1%
Elite Pharmaceuticals Inc (ELTP)	2026-03-31	$73.85M	+68.0%
Macrogenics Inc (MGNX)	2025-12-31	$0	-100.0%
Heron Therapeutics, Inc. (HRTX)	2025-12-31	$41.35M	+7.0%
Liquidia Corp (LQDA)	2024-12-31	$5.88M	+103.6%
Standard Biotools Inc. (LAB)	2025-12-31	$42.79M	-7.2%

Compare GYRE, URGN, LFCR, SIGA side by side · Screen every company in Pharmaceutical Preparations ↗